MK-801 and amphetamine result in dissociable profiles of cognitive impairment in a rodent paired associates learning task with relevance for schizophrenia

RationalePaired associates learning (PAL) has been suggested to be predictive of functional outcomes in first episode psychosis and of conversion from mild cognitive impairment to Alzheimer’s disease. An automated touch screen-based rodent PAL (rPAL) task has been developed and is sensitive to manipulations of the dopaminergic and glutamatergic system. Accordingly, rPAL when used with pharmacological models of schizophrenia, like NMDA receptor blockade with MK-801 or dopaminergic stimulation with amphetamine, may have utility as a translational model of cognitive impairment in schizophrenia.ObjectiveThe purpose of this study was to determine if amphetamine- and MK-801-induced impairment represent distinct models of cognitive impairment by testing their sensitivity to common antipsychotics and determine the relative contributions of D1 versus D2 receptors on performance of PAL.MethodRats were trained in rPAL and were then treated with MK-801, amphetamine, risperidone, haloperidol, quinpirole, SK-82958, or SCH-23390 alone and in combination.ResultsWhile both amphetamine and MK-801 caused clear impairments in accuracy, MK-801 induced a profound “perseverative” type behavior that was more pronounced when compared to amphetamine. Moreover, amphetamine-induced impairments, but not the effects of MK-801, could be reversed by antipsychotics as well as the D1 receptor antagonist SCH-23390, suggesting a role for both the D1 and D2 receptor in the amphetamine impairment model.ConclusionsThese data suggest that amphetamine and MK-801 represent dissociable models of impairment in PAL, dependent on different underlying neurobiology. The ability to distinguish dopaminergic versus glutamatergic effects on performance in rPAL makes it a unique and useful tool in the modeling of cognitive impairments in schizophrenia.

[1]  D. Sulzer,et al.  Mechanisms of neurotransmitter release by amphetamines: A review , 2005, Progress in Neurobiology.

[2]  Thomas Steckler,et al.  Touching on translation , 2013, Cell and Tissue Research.

[3]  Peter B. Jones,et al.  Visuospatial learning and executive function are independently impaired in first-episode psychosis , 2005, Psychological Medicine.

[4]  J. Hagan,et al.  Predicting drug efficacy for cognitive deficits in schizophrenia. , 2005, Schizophrenia bulletin.

[5]  J. Hsu,et al.  Does the dopamine hypothesis explain schizophrenia? , 2013, Reviews in the neurosciences.

[6]  Thomas Steckler,et al.  A touch-screen based paired-associates learning (PAL) task for the rat may provide a translatable pharmacological model of human cognitive impairment , 2014, Pharmacology Biochemistry and Behavior.

[7]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[8]  B. Angrist,et al.  Amphetamine psychosis: behavioral and biochemical aspects. , 1974, Journal of psychiatric research.

[9]  T. Steckler,et al.  NMDA receptors, cognition and schizophrenia – Testing the validity of the NMDA receptor hypofunction hypothesis , 2012, Neuropharmacology.

[10]  S. Robertson,et al.  A Closer Look at Amphetamine-Induced Reverse Transport and Trafficking of the Dopamine and Norepinephrine Transporters , 2009, Molecular Neurobiology.

[11]  Richard D Emes,et al.  Synaptic scaffold evolution generated components of vertebrate cognitive complexity , 2012, Nature Neuroscience.

[12]  C. Tamminga,et al.  Schizophrenia and glutamatergic transmission. , 1998, Critical reviews in neurobiology.

[13]  L. Saksida,et al.  A novel touchscreen-automated paired-associate learning (PAL) task sensitive to pharmacological manipulation of the hippocampus: a translational rodent model of cognitive impairments in neurodegenerative disease , 2009, Psychopharmacology.

[14]  A. Belger,et al.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development , 2003, Psychopharmacology.

[15]  Anissa Abi-Dargham,et al.  Do we still believe in the dopamine hypothesis? New data bring new evidence. , 2004, The international journal of neuropsychopharmacology.

[16]  T. Robbins,et al.  Assessing cognitive function in clinical trials of schizophrenia , 2010, Neuroscience & Biobehavioral Reviews.

[17]  Andrew D. Blackwell,et al.  Detecting Dementia: Novel Neuropsychological Markers of Preclinical Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[18]  A C Roberts,et al.  Synergistic and Regulatory Effects of Orbitofrontal Cortex on Amygdala‐Dependent Appetitive Behavior , 2007, Annals of the New York Academy of Sciences.

[19]  T. Bussey,et al.  Neuroscience and Biobehavioral Reviews Testing Long-term Memory in Animal Models of Schizophrenia: Suggestions from Cntrics , 2022 .

[20]  Thomas Steckler,et al.  Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models , 2009, Neuropsychopharmacology.

[21]  Stefan Kasicki,et al.  A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo , 2013, Journal of psychopharmacology.

[22]  G. Collingridge,et al.  Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism , 1986, Nature.

[23]  The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli , 2012, Psychopharmacology.

[24]  B. Bogerts,et al.  The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue , 2014, Front. Psychiatry.